{"id":6190,"date":"2019-12-07T15:47:57","date_gmt":"2019-12-07T14:47:57","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/hohe-investorendichte-auf-dem-pitch-day-im-izb\/"},"modified":"2020-07-13T13:51:33","modified_gmt":"2020-07-13T11:51:33","slug":"hohe-investorendichte-auf-dem-pitch-day-im-izb","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/hohe-investorendichte-auf-dem-pitch-day-im-izb\/","title":{"rendered":"High investor density at the Pitch Day hosted by the IZB"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

High investor density at the Pitch Day hosted by the IZB<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]December 2019[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”6184″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Investors at the 5th Munich Life Science Pitch Day 2019 (f.l.t.r.):
\nDr. Joachim Vogt<\/strong>, AbbVie Inc., Fis Emri<\/strong>, Saverna Therapeutics, Andreas Huber<\/strong>, Bayern Kapital, Dr. Holger Reithinger<\/strong>, Forbion Capital Partners, Annegret de Baey-Diepolder<\/strong>, Seventure Partners, Dr. Marianne Mertens<\/strong>, Wellington Partners Advisory AG, Dr. Joachim Rothe<\/strong>, Life Sciences Partners, Thomas M\u00f6ller<\/strong>, BioMedPartners AG, Laurent Jacqueroud<\/strong>, Kurma Partners SA, Dr. Ioannis Sapountzis<\/strong>, Boehringer Ingelheim, Dr. Bernd Goergen<\/strong>, HTGF, Christoph Kocher<\/strong>, Gimv, Daniel Parera<\/strong>, TVM Life Science Management GmbH, Dr. Marie Asano<\/strong>, HTGF, Dr. Lena Krzyzak<\/strong>, HTGF, Dr. Daniel Dillinger<\/strong>, Redalpine Venture Partners AG, Dr. Benedikt Luhmann<\/strong>, VI Partners AG, C\u00e9dric Barra<\/strong>, Occident Group AG, Dr. Peter Neubeck<\/strong>, Kurma Partners SA[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Twelve project teams presented their top-class research to 25 VCs<\/strong><\/p>\n

Together with Bayer AG and Boehringer Ingelheim as strategic partners, the High-Tech Gr\u00fcnderfonds (HTGF) and the Innovation and Start-up Center Biotechnology (IZB) in Martinsried near Munich organized the \u201c5th Munich Life Science Pitch Day\u201d held on July 11, 2019 at the Faculty Club of the IZB. Twenty-nine project teams applied for the Pitch Day and twelve selected start-ups got the chance to present themselves to \u00ad25 investors. Dr. Lena Krzyzak, Senior Investment Manager of HTGF, moderated the event. The opening speeches were held by Dr. Peter Hanns Zobel (Managing Director of the IZB), Prof. Stefan Jaroch (Head of Strategic Technology Partnerships, Bayer AG), Dr. Marianne Mertens (Principal, Wellington Partners Life Science Venture Capital), Dr. Lena Krzyzak (Senior Investment Manager, High-Tech Gr\u00fcnderfonds) and Dr. Ioannis Sapountzis (Global Head BD&L, Boehringer Ingelheim).[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner][vc_single_image image=”6186″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Partners of the 5th Munich Life Science Pitch Day at the IZB (f.l.t.r.):
\nDr. Peter Hanns Zobel<\/strong>, Managing Director, IZB, Prof. Dr. Stefan Jaroch<\/strong>, Head of Strategic Technology Partnerships, Bayer AG, Dr. Lena Krzyzak<\/strong>, Senior Investment Manager, High-Tech Gr\u00fcnderfonds, Dr. Ioannis Sapountzis<\/strong>, Global Head BD&L, Boehringer Ingelheim[\/vc_column_text][vc_single_image image=”6188″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Project teams at the 5th Munich Life Science Pitch Day 2019
\n(f.l.t.r.): Dr. Kamal Azzaoui<\/strong>, Saverna Therapeutics; Prof. Dr. Matthias Mack<\/strong>, ImmuCon; Dr. Tim Horlacher<\/strong>, SiBreaX; Dr. Marius Yildiz<\/strong>, Avergen; Dr. Jens Kelm<\/strong>, PreComb; Dr. Thomas Taapken<\/strong>, Bluehaven; Alexander Schueller<\/strong>, CellVita; Dr. Ing. Miriam Haerst<\/strong>, Kumovis; \u00adProf. Dr. Eric Hesse<\/strong>, Sirana Pharma GmbH; Dr. Nadja Fenn<\/strong>, Opsyon; Dr. Cornelius Sobel<\/strong>, Actitrexx; Dr. Francisco Pan-Montojo<\/strong>, Jochen Rheinwald<\/strong>, both Glymipro[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]In his keynote speech, Dr. Daniel Vitt, CEO of Immunic, Inc., described the path from start-up to\u00a0 stockmarket company on NASDAQ in just three years. Top-calibre research ranging from the introduction of silicate nanoparticles as a new drug delivery system, a microRNA approach to the loss of bone mass and muscle function, the development of novel cancer therapeutics, humanized antibodies for the treatment of MS\/SLE patients, and increased efficacy of medications in the context of organ transplants. Fifty-five guests attended the event.
\n[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n